XNASSTOK
Market cap562mUSD
Jan 24, Last price
10.62USD
1D
0.19%
1Q
-10.83%
IPO
-59.15%
Name
Stoke Therapeutics Inc
Chart & Performance
Profile
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
IPO date
Jun 19, 2019
Employees
117
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | |||||||
Revenues | 8,780 -29.22% | 12,405 | |||||
Cost of revenue | 123,553 | 120,296 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (114,773) | (107,891) | |||||
NOPBT Margin | |||||||
Operating Taxes | (7,957) | ||||||
Tax Rate | |||||||
NOPAT | (114,773) | (99,934) | |||||
Net income | (104,699) 12.45% | (93,110) 9.91% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 52,081 | 46,408 | |||||
BB yield | -22.51% | -12.93% | |||||
Debt | |||||||
Debt current | 2,388 | 2,359 | |||||
Long-term debt | 2,062 | 5,076 | |||||
Deferred revenue | 33,074 | 36,856 | |||||
Other long-term liabilities | 4,884 | 2,968 | |||||
Net debt | (196,944) | (222,729) | |||||
Cash flow | |||||||
Cash from operating activities | (81,067) | (31,866) | |||||
CAPEX | (1,616) | (3,962) | |||||
Cash from investing activities | 105,946 | (45,882) | |||||
Cash from financing activities | 53,007 | 46,409 | |||||
FCF | (115,779) | (102,284) | |||||
Balance | |||||||
Cash | 201,394 | 229,595 | |||||
Long term investments | 569 | ||||||
Excess cash | 200,955 | 229,544 | |||||
Stockholders' equity | (401,868) | (298,321) | |||||
Invested Capital | 601,453 | 528,070 | |||||
ROIC | |||||||
ROCE | |||||||
EV | |||||||
Common stock shares outstanding | 43,995 | 38,897 | |||||
Price | 5.26 -43.01% | 9.23 -61.53% | |||||
Market cap | 231,413 -35.54% | 359,023 -59.27% | |||||
EV | 34,469 | 136,294 | |||||
EBITDA | (112,304) | (106,345) | |||||
EV/EBITDA | |||||||
Interest | 3,122 | ||||||
Interest/NOPBT |